We create tailor-made antibodies and assays to quantify unique biomarkers in a wide variety of neurodegenerative diseases and conditions such as Alzheimer’s disease, Parkinson’s disease and traumatic brain injury. Our assays enable early detection before symptoms appear, providing valuable information from the drug development phase up to clinical practice, to improve the life of patients.
State-of-the-art biomarker assays for
neurodegenerative diseases
We create tailor-made antibodies and assays to quantify unique biomarkers in a wide variety of neurodegenerative diseases and conditions such as Alzheimer’s disease, Parkinson’s disease and traumatic brain injury. Our assays enable early detection before symptoms appear, providing valuable information from the drug development phase up to clinical practice, to improve the life of patients.
Discover our portfolio
Read the latest news
Scientific articles in 2025
Scientific articles in 2025
Join us at the 36th International Symposium on ALS/MND
Join us at the 36th International Symposium on ALS/MND
Join us at CTAD 2025
Join us at CTAD 2025
Join us at ADPD 2025
Join us at ADPD 2025
Pharmaceutical Companies
Biomarkers increase clinical trial success and help deliver the right drugs to the right patients. We support pharmaceutical companies by developing biomarkers from antibody to qualified assay, creating robust and reliable solutions that facilitate your drug development journey. With deep expertise in biomarker biology, optimized antibody generation, and fit-for-purpose assay design, we enable early measurement of the neuro biomarkers you need, tailored to their specific context-of-use, whether for target engagement, patient selection, or clinical interpretation, allowing you to stay in the driver’s seat while we take care of everything needed to advance your biomarker toward clinical impact.
Technology Providers
Through years of experience, we have mastered the true craftsmanship required for creating, selecting and producing optimally performant antibodies. We identify the best antibody combinations for each application and develop robust assays, adaptable to any platform. Our extensive portfolio of state-of-the-art antibodies, built through in-house research and academic collaborations, provides qualified materials ready for exploration in clinical research and practice.
Our expertise
ADx bridges the gap between pharma and IVD companies, building partnerships to support innovations that can truly change the life of the patients with neurodegenerative conditions. Our management team combines more than 45 years of experience with an impressive track record developing superior diagnostic biomarkers.